Chembio CEO Announces Retirement for May 2014

Chembio CEO Announces Retirement for May 2014

MEDFORD, N.Y., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics,
Inc.(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious
diseases, today announced that Lawrence A. Siebert has stated his intention to
retire from his positions as chief executive officer and president of the
company and its wholly-owned subsidiary when his current employment agreement
expires May 11, 2014. The board of directors is now commencing a search for a
new CEO.

"Larry has been with Chembio for 21 years, 11 of which as CEO," stated Gary
Meller, Chembio director. "During that time, Chembio has been transformed into
a strong and sustainable business with a growing pipeline of new products. We
thank Larry for his leadership and many contributions to Chembio and wish him
well in the future."

"Chembio today is a leading point-of-care diagnostic company," stated Lawrence
A. Siebert. "Our business is growing and our future pipeline is more promising
than ever. Equally important, we've built a strong leadership team throughout
the company that is exceedingly capable of expanding the business in both the
U.S.and worldwide. I will leave the company in the hands of a highly qualified
management group and I know the transition will be seamless."

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485.For more
information, please visit:

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties.Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         631-924-1135, ext. 125
         Vida Strategic Partners (investor relations)
         Stephanie C. Diaz
Press spacebar to pause and continue. Press esc to stop.